Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Engineered AAV Capsid Design and Analytics

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Engineered AAV Capsid Design and Analytics

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence in AAV Vector Engineering.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Executive Summary

Pre-existing immunity to naturally occurring adeno-associated virus (AAV) serotypes presents a significant barrier to patient eligibility and therapeutic efficacy. Engineered capsids offer a path to overcome this challenge by altering tropism and evading neutralizing antibodies (NAbs). This requires a sophisticated analytical and manufacturing framework to characterize novel vectors and build a robust data package for regulatory submissions. Franklin Biolabs provides the specialized production and analytical capabilities necessary to support the design, screening, and preclinical validation of next-generation AAV therapies, aligning vector performance with global CMC expectations.

Frequently Asked Questions

How does engineered capsid design address the limitations of natural AAV immunogenicity?

Engineered capsids are rationally designed to alter the surface-exposed residues that are recognized by pre-existing neutralizing antibodies in the patient population. By modifying these epitopes, the goal is to create vectors that can evade the host immune system, thereby expanding patient access and potentially enabling lower, more effective dosing.

What specific analytical support is required for novel AAV vectors in IND-enabling programs?

Novel AAV vectors demand a comprehensive and customized analytical strategy beyond standard assays. This includes developing vector-specific potency assays to confirm biological function, advanced sequencing to verify capsid and genome integrity, and rigorous characterization of purity and particle attributes. These analytics form the core of the CMC data package for IND submissions that comply with harmonized ICH guidelines.

Can a single epitope mutation allow an AAV to completely evade neutralizing antibodies?

No, a single mutation is generally insufficient. While mapping and modifying a specific neutralizing epitope can reduce binding from a corresponding monoclonal antibody, the human immune response is polyclonal, involving multiple antibodies targeting different sites on the capsid. A successful immune-evasion strategy often requires a more comprehensive approach to capsid engineering to address this complexity.

The Challenge of Pre-existing AAV Immunity

The clinical application of naturally occurring AAV serotypes is constrained by the prevalence of pre-existing NAbs in the general population. This immunity can neutralize the vector before it reaches its target tissue, rendering the therapy ineffective. Consequently, sponsors are increasingly turning to the rational design of novel and engineered capsids to bypass this immunological hurdle.

This engineering effort moves beyond simple serotype selection. It involves a data-driven process of identifying and modifying specific capsid residues to detarget NAbs while retaining or enhancing desired tissue tropism.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

A Realistic Approach to Immune Evasion

Scientific investigations into NAb evasion provide a clear directive for capsid engineering strategies. Mapping a specific neutralizing epitope on a capsid like AAV9 is a foundational step in understanding immune recognition (PMID: 30089698). However, this same work underscores that a single point mutation, while effective against a specific monoclonal antibody, does not confer broad protection against a polyclonal immune response.

A successful program requires a more extensive strategy. Franklin Biolabs supports this by providing the framework to produce and analyze libraries of capsid variants, enabling sponsors to screen for candidates with the most favorable immune-evasion and performance profiles.

Our support for engineered capsid programs includes:

  • High-throughput research-grade production of diverse capsid variants for in vitro and in vivo screening.

  • Development of custom, phase-appropriate analytical methods to characterize novel vector identity, purity, and strength.

  • In-depth assessment of vector tropism and transduction efficiency in relevant biological systems.

Our partners value this approach. As one biotech partner noted, our team has “Vast knowledge in all aspects of vector production and analytics.”

Aligning Novel Vectors with Global Regulatory Submissions

Introducing an engineered capsid into a therapeutic program necessitates a rigorous CMC data package. Regulatory bodies require extensive characterization to ensure the novel vector is safe, pure, and potent. Our >100,000 sq ft facility is equipped to generate the data required for multi-jurisdictional IND and IMPD submissions.

The scientific leadership and core team at Franklin Biolabs have leveraged this expertise to achieve a 100% successful IND rate since 2019, a track record established prior to our formal launch in 2024. This history enables us to guide programs toward an 18-24 month IND timeline. For a deeper look into program initiation and capsid considerations, our webinar on AAV project success provides additional context.

This work is foundational to the development of next-generation AAV therapies and is a core competency within our broader Vector | CMC | Analytics Services.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities